The National Cardiovascular Health Program

 

This program supports extensive scientific evidence, links nonmedical factors, including systemic racism and the lack of economic opportunities, with poor health outcomes and increased mortality rates, all of which are preventable. Factors such as poverty, inadequate housing, poor health care, and other debilitating social conditions, commonly referred to as social determinants of health, contribute to long-standing disparities and health inequities. These social conditions contribute to the increased prevalence of cardiovascular disease (CVD) in the US population. CVD is the leading cause of death in the US; stroke is the 5th leading cause. In 2020, about 1 in 5 adults who died from CVD were younger than 65 years old. It is estimated that 1 in 9 health care dollars are spent on CVD. CVD mortality rates declined for several decades due to both clinical and public health interventions, but recently declining death rates from both heart disease and stroke have stalled. One reason is that hypertension, the primary risk factor for CVD, is very common (1 in 2 US adults has hypertension) but control is not. Only 1 in 4 adults with hypertension (26.1%) has it under control. Gains have been made in treating high cholesterol, another primary risk factor for CVD. Overall, the age-adjusted prevalence of high cholesterol decreased from 21% to 10% from 19881994 to 20172018. This improvement is due in part to individuals healthy behaviors such as eating a healthy diet, losing weight, being physically active, and medication adherence, along with clinical contributions from appropriate prescribing and intensification of medication. Additional public health and health system interventions aimed at preventing, detecting, and controlling elevated cholesterol and blood pressure can help to further decrease CVD mortality. This program aims to implement and evaluate evidence-based strategies contributing to the prevention and management of CVD in populations disproportionately at risk. Given the importance of health equity, this program addresses social and economic factors to help communities and health systems respond to social determinants present in their communities to offer those at risk of or burdened with CVD the best health outcomes possible.

Active 93.426 Centers For Disease Control and Prevention, Department of Health and Human Services B - Project Grants Not applicable. Section 301(a) and 317(k)(2) of the Public Health Service Act [42] U.S.C. Section 241(a) and 247b(k)(2) Title IV Section 4002 of the Affordable Care Action, Prevention and Public Health Fund State Governments or their Bona Fide Agents (includes the District of Columbia) are eligible Beneficiaries of this program include: State, Local, Individual/Family, Minority Group, Anyone/General Public, Black American, American Indian, Spanish Origin, Oriental, Other Nonwhite, Women, Handicapped, Physically Afflicted, Senior Citizen, Rural Not applicable. Preapplication coordination is required. This program is eligible for coverage under E.O. 12372, "Intergovernmental Review of Federal Programs." An applicant should consult the office or official designated as the single point of contact in his or her State for more information on the process the State requires to be followed in applying for assistance, if the State has selected the program for review. Refer to the NOFO posted on grants.gov for additional information. This program is excluded from coverage under 2 CFR 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards. After review and approval, a Notice of Award (NoA) will be prepared and processed, along with appropriate notification to the public. Initial awards provide funds for the first budget period (usually 12 months) and the NoA will indicate support recommended for the remainder of the project period, allocation of Federal funds by budget categories, award requirements, and special conditions, if any. Check Grants.gov for any relevant NOFO information regarding processes for applying for assistance. From 120 to 180 days. Applications will be evaluated and approved or disapproved within 180 days of submission to the Federal Agency Not applicable. More than 180 days. Cooperative agreement period of performance is 1 to 5 years. After initial awards, and subject to availability of funds, projects may be continued non-competitively contingent upon satisfactory progress by the recipient (as documented in required reports) and the determination that continued funding is in the best interest of the Federal government. Applications will be evaluated on the review criteria described in the Notices of Funding Opportunity (NOFOs). In general, the review and selection process of complete and responsive applications to the NOFO consists of determination of the scientific and technical merit by objective or peer review, availability of funds, and relevance of program priorities and the priorities of CDC. Funds for this program are to be used to implement and evaluate evidence-based strategies to address the challenges and systemic barriers that contribute to prevention and management of cardiovascular disease and diabetes in high-burden populations. Performance Reports: Annual Federal Financial Reports (FFR) and performance/progress reports are required. Final FFRs and performance reports are required. Other reporting may be required and will be outlined in the NOFO or the Notice of Award. Not applicable. In accordance with 2 CFR ?200, as codified in 45 CFR ?75, there is a 3-year record retention requirement; records shall be retained beyond the 3-year period if final audit has not been done or findings resolved. Property records must be retained in accordance with HHS Grants Policy Statement requirements. Statutory formula is not applicable to this assistance listing.

Matching requirements are not applicable to this assistance listing.

MOE requirements are not applicable to this assistance listing. Financial assistance is provided for a 12-month budget period with a period of performance of up to five years subject to the availability of funds and satisfactory progress of the recipient. Notice of Award None/Not specified. Sheryl Heard
4770 Buford Highway, NE
Atlanta, GA 30341 US
slh3@cdc.gov
Phone: 7704882855 75-0943-0-1-550 (Project Grants) FY 22$81,993,530.00; FY 23 est $55,000,000.00; FY 24 est $55,000,000.00; FY 21$110,000,000.00; FY 20$99,303,968.00; FY 19$110,000,000.00; FY 18$90,000,002.00; FY 17$0.00; - Average award $1,000,000 Range $850,000 - $2,000,000 Not applicable. Not applicable.